Feugier Pierre, Bensoussan Daniele, Girard Florence, Alla Francois, Schuhmacher Anne, Latger-Cannard Veronique, Hulin Cyrille, Witz Francis, Witz Brigitte, Carret Anne Sophie, Bordigoni Pierre, Lederlin Pierre, Janot Christian
Department of Hematology, University Hospital, Nancy, France.
Transfusion. 2003 Jul;43(7):878-84. doi: 10.1046/j.1537-2995.2003.00446.x.
The implementation of a quality-assurance program is a major requirement to ensure quality and safety of the final PBPC components intended for clinical use. It is not clear whether the quantification of CFU-GM and CD34+ cells should be done on fresh components and after cryopreservation, which better represents the actual composition of the graft.
Correlation between prefreeze and postthaw MNCs, CD34+ cells, and CFU-GM collected from 126 patients undergoing BMT (n=43) or PBPC (n =83) transplantation were evaluated. The statistical incidence of prefreeze and postthaw parameters as well as patient characteristics and conditioning regimens on hematologic recovery were analyzed.
By multivariate analysis, prefreeze and postthaw CD34+ cells were the only two variables significantly and independently correlated to hematologic recovery. Low prefreeze and postthaw CD34+ cell numbers associated to a low CD34+ yield characterize PBPC grafts from patients who have the slowest hematologic recovery. The postthaw PBPC CD34+ cell number can be estimated before conditioning regimen by thawing a small aliquot of the graft.
In association to prefreeze CD34+ cell number and to CD34+ yield, postthaw CD34+ cell number may be useful in monitoring cell loss during processing and identifying patients at risk of slow PBPC engraftment.
实施质量保证计划是确保临床使用的最终外周血祖细胞（PBPC）成分质量和安全的主要要求。目前尚不清楚集落形成单位 - 粒细胞 - 巨噬细胞（CFU - GM）和CD34 +细胞的定量应在新鲜成分上进行还是在冷冻保存后进行，而后者更能代表移植物的实际组成。
评估了从126例接受骨髓移植（n = 43）或外周血祖细胞移植（n = 83）的患者中收集的冻前和冻后单核细胞（MNC）、CD34 +细胞和CFU - GM之间的相关性。分析了冻前和冻后参数以及患者特征和预处理方案对血液学恢复的统计学发生率。
通过多变量分析，冻前和冻后CD34 +细胞是仅有的两个与血液学恢复显著且独立相关的变量。冻前和冻后CD34 +细胞数量低且CD34 +产量低的情况，是血液学恢复最慢的患者的PBPC移植物的特征。在预处理方案之前，可以通过解冻一小份移植物来估计冻后PBPC CD34 +细胞数量。
结合冻前CD34 +细胞数量和CD34 +产量，冻后CD34 +细胞数量可能有助于监测处理过程中的细胞损失，并识别外周血祖细胞植入缓慢风险的患者。
